Amgen (AMGN) Enterprise Value (2009 - 2026)
Amgen (AMGN) posted quarterly Enterprise Value of -$12.0 billion for Q1 2026, down 36.64% year-over-year from -$19.0 billion in Q1 2025, and down 31.87% on a QoQ basis from -$9.1 billion in Q4 2025.
Amgen (AMGN) Enterprise Value (2009 - 2026) Analysis & Trends
Amgen (AMGN) has reported Enterprise Value for 18 consecutive years, with -$12.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 36.64% year-over-year to -$12.0 billion; the TTM figure through Mar 2026 stood at -$12.0 billion (down 36.64% YoY), while the FY2025 annual figure was -$9.1 billion, up 23.75% from the prior year.
- Enterprise Value came in at -$12.0 billion for Q1 2026 at Amgen, down from -$9.1 billion in the prior quarter.
- The five-year high for Enterprise Value was -$6.5 billion in Q1 2022, with the low at -$34.7 billion in Q3 2023.
- Average Enterprise Value over 5 years is -$13.7 billion, with a median of -$9.4 billion recorded in 2025.
- Across the five-year window, Enterprise Value tumbled 382.29% in 2023 and surged 74.06% in 2024, its largest moves.
- Year by year, Enterprise Value stood at -$9.3 billion in 2022, then fell by 17.61% to -$10.9 billion in 2023, then fell by 9.4% to -$12.0 billion in 2024, then advanced by 23.75% to -$9.1 billion in 2025, then plunged by 31.87% to -$12.0 billion in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$12.0 billion, -$9.1 billion, and -$9.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -5.28 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -22.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -9.35 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -7.89 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 315.00 Mn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | -4.28 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.04 Bn |
| Dec 31, 2025 | -9.13 Bn |
| Sep 30, 2025 | -9.45 Bn |
| Jun 30, 2025 | -8.03 Bn |
| Mar 31, 2025 | -8.81 Bn |
| Dec 31, 2024 | -11.97 Bn |
| Sep 30, 2024 | -9.01 Bn |
| Jun 30, 2024 | -9.30 Bn |
| Mar 31, 2024 | -9.71 Bn |
| Dec 31, 2023 | -10.94 Bn |
| Sep 30, 2023 | -34.74 Bn |
| Jun 30, 2023 | -34.25 Bn |
| Mar 31, 2023 | -31.56 Bn |
| Dec 31, 2022 | -9.31 Bn |
| Sep 30, 2022 | -11.48 Bn |
| Jun 30, 2022 | -7.18 Bn |
| Mar 31, 2022 | -6.54 Bn |
| Dec 31, 2021 | -8.04 Bn |
| Sep 30, 2021 | -12.92 Bn |
| Jun 30, 2021 | -8.08 Bn |